Diffusion Pharmaceuticals Inc. (DFFN) |
| 4.4 0.41 (10.28%) 08-16 16:00 |
| Open: | 4.23 |
| High: | 5.19 |
| Low: | 4.165 |
| Volume: | 349,445 |
| Market Cap: | 9(M) |
| PE Ratio: | -0.62 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 5.19 |
| Resistance 1: | 4.80 |
| Pivot price: | 0.00 |
| Support 1: | 4.16 |
| Support 2: | 3.47 |
| 52w High: | 14.37 |
| 52w Low: | 4.139999 |
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
Financials
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Tue, 15 Aug 2023
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma - Yahoo Finance
Thu, 30 Mar 2023
EIP Pharma and Diffusion Pharmaceuticals Announce Merger - GlobeNewswire
Thu, 30 Mar 2023
EIP Pharma and Diffusion Pharmaceuticals to Merge - citybiz
Thu, 17 Nov 2022
LifeSci Special Opportunities Responds to Recent Press Release Issued by Diffusion Pharmaceuticals - Yahoo Finance
Wed, 17 Feb 2021
Diffusion Pharmaceuticals Announces Closing of $30 Million Bought Deal Offering of Common Stock - Stock Titan
Tue, 25 Aug 2020
Board of Directors - CytoDyn Inc.
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
